| Aug 1 |
Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics
|
| Jul 30 |
Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)
|
| Jul 24 |
Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease Bimarker
|
| Jul 24 |
Vigil Neuroscience reports interim data from its once-daily oral therapy for Alzheimer’s
|
| Jul 24 |
Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
|
| Jul 18 |
Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference
|
| Jul 18 |
Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP
|
| Jun 27 |
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
|
| Jun 27 |
Biggest stock movers today: BB, MU, and more
|
| Jun 27 |
Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
|
